Second Class Minors: Molecular Identification of the Autosomal H46 Histocompatibility Locus as a Peptide Presented by Major Histocompatibility Complex Class II Molecules by Sahara, Hiroeki & Shastri, Nilabh
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2003/02/375/11 $8.00
Volume 197, Number 3, February 3, 2003 375–385
http://www.jem.org/cgi/doi/10.1084/jem.20021961
 
375
 
Second Class Minors: Molecular Identiﬁcation of the 
 
Autosomal 
 
H46
 
 Histocompatibility Locus as a Peptide 
Presented by Major Histocompatibility Complex
Class II Molecules
 
Hiroeki Sahara and Nilabh Shastri
 
Division of Immunology, Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720
 
Abstract
 
CD4 T cells regulate immune responses that cause chronic graft rejection and graft versus host
disease but their target antigens remain virtually unknown. We developed a new method to
identify CD4 T cell–stimulating antigens. LacZ-inducible CD4 T cells were used as a probe to
detect their cognate peptide/MHC II ligand generated in dendritic cells fed with 
 
Escherichia coli
 
expressing a library of target cell genes. The murine 
 
H46
 
 locus on chromosome 7 was thus
found to encode the interleukin 4–induced 
 
IL4i1
 
 gene. The IL4i1 precursor contains the
HAFVEAIPELQGHV peptide which is presented by A
 
b
 
 major histocompatibility complex
 
class II molecule via an endogenous pathway in professional antigen presenting cells. Both allelic
peptides bind A
 
b
 
 and a single alanine to methionine substitution at p2 defines nonself. These
results reveal novel features of 
 
H
 
 loci that regulate CD4 T cell responses as well as provide a
general strategy for identifying elusive antigens that elicit CD4 T cell responses to tumors or
self-tissues in autoimmunity.
Key words: transplantation • antigens • antigen processing • CD4 T cells • GVHD
 
Introduction
 
The histocompatibility 
 
H
 
 loci are polymorphic genes that
determine the outcome of transplanted tissue grafts as well as
graft versus host disease reactions in both mouse and man (1,
2). Despite the complete match of MHC molecules be-
tween the donor and host strains natural polymorphisms
within the 
 
H
 
 loci result in the presentation of novel peptides
by the MHC to T cells (3). For example, different 
 
H
 
 loci lo-
cated on the male Y chromosome encode peptides that are
presented by both MHC I and MHC II molecules and elicit
potent CD8 and CD4 responses respectively (4, 5). At least
60 
 
H
 
 loci, located largely on autosomal chromosomes are
known to exist in mice and a similar number is likely to be
present in the human as well (2). Determining the molecu-
lar identity of 
 
H
 
 loci is critical not only because of their clin-
ical relevance but also for understanding the fundamental
mechanisms that make the H antigens immunogenic within
the context of highly complex mammalian cells.
In recent years several 
 
H
 
 loci have been identified at the
molecular level as the source of naturally processed peptides
presented by MHC I molecules to CD8 T cells (6, 7, and
references therein). In contrast, despite the appreciation of
their critical role in regulating immune responses to tissue
grafts and tumors (8, 9), the 
 
H
 
 loci that encode antigenic
peptides presented by MHC II molecules to CD4 T cells
remain virtually unknown at the molecular level. For in-
stance it is not known whether the genetically defined 
 
H
 
loci that regulate CD4 T cell responses do so because they
encode the antigenic peptides or because they directly or
indirectly regulate the MHC II antigen processing pathway
as seen for one of the CD8 T cell defined human H antigen
(10). It is also unclear whether professional APCs acquire
the H antigens from exogenous sources as are most antigens
presented by MHC II molecules or whether processing of
H peptide/MHC II utilizes precursors synthesized endoge-
nously within the professional APCs (11). The recently dis-
covered Y chromosome encoded Dby H antigen was pre-
sented by MHC II when professional dendritic cells (DCs)
 
*
 
acquired it from other cells expressing the 
 
Dby
 
 gene (5).
 
H. Sahara’s present address is Marine Biomedical Institute, Sapporo Med-
ical University School of Medicine, Rishirifuji-cho, Hokkaido 097-0101,
Japan.
Address correspondence to Nilabh Shastri Division of Immunology,
LSA 421, Department of Molecular and Cell Biology, University of Cali-
fornia, Berkeley, CA 94720-3200. Phone: 510-643-9197; Fax: 510-643-
9230; E-mail: nshastri@socrates.berkeley.edu
 
*
 
Abbreviations used in this paper:
 
 BMDC, bone marrow–derived immature
DC; DC, dendritic cell.T
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Whether this is a general paradigm for all CD4 T cell–
defined 
 
H
 
 loci is unclear. Finally, to what extent the donor
H antigens differ from self to elicit potent CD4 T cell re-
sponses remains to be determined.
The relative success in the identification of CD8 T cell–
stimulating 
 
H
 
 loci is due to the availability of robust meth-
ods for expression cloning the antigenic precursor genes or
for biochemical purification and identification of the pro-
cessed antigenic peptides (12–14). By contrast, the identifi-
cation of CD4 T cell–stimulating antigens has remained an
extraordinarily difficult task. Unlike the homogenous pep-
tides presented by MHC class I, the peptides presented by
MHC class II are heterogeneous with varying N- and
COOH termini flanking the core antigenic peptide (11,
15–17). Peptides eluted from MHC II therefore do not
elute in a single peak when fractionated by HPLC and are
thus difficult to purify. The peptide purification problem is
further magnified by the generally low sensitivity of CD4
T cells to exogenous antigens, in the nano to micromolar
concentration range. In comparison, CD8 T cells respond
to exogenous peptides at femto to picomolar concentra-
tions which makes it simpler to follow the purification of
endogenously processed peptides from the target cells.
The expression cloning strategies for identifying CD4 T
cell antigens are also challenging. The MHC I presentation
pathway operates in almost all cell types, and it is usually
sufficient to introduce an antigen encoding cDNA to ob-
tain expression of the peptide/MHC I ligand (18). By con-
trast, the MHC class II processing pathway operates
primarily in professional APCs (11). These APCs are spe-
cialized to present antigenic peptide/MHC II complexes
from exogenous proteins but endogenously synthesized
proteins are usually excluded. Thus, even if antigenic pre-
cursors were expressed in the professional APCs, their pre-
sentation as peptide/MHC II complexes may not occur.
We and others circumvented this problem by targeting an-
tigenic precursors directly into the MHC II processing
compartment by expressing them as invariant chain fusion
proteins, which significantly improved the efficiency with
which peptide/MHC II complexes were generated (19,
20). Nevertheless, the limitations in transfection efficiency
have so far precluded the use of this method in professional
APCs. The invariant chain/fusion protein strategy has so
far been successful only in specially engineered, readily
transfectable cell lines allowing the identification of several
CD4 T cell–stimulating tumor antigens (21, 22). In an ele-
gant method that combined the expression of target anti-
gen in transfectable cell lines with the use of DCs as profes-
sional APCs, the Simpson group recently identified the
Y-chromosome encoded 
 
Dby
 
 gene as the source of pep-
tides presented by the A
 
b
 
 and E
 
k
 
 MHC class II molecules to
CD4 T cells (5). This method is presently limited to single
candidate genes and has thus far not permitted the screen-
ing of complex cDNA libraries.
Here we developed a new method for identifying CD4
T cell stimulating antigens in mammalian cells containing
thousands of potential precursors. The p/MHC II ligands
were generated in professional APCs fed with pools of re-
 
combinant 
 
Escherichia coli 
 
expressing the target antigens. We
took advantage of the high phagocytic and antigen presen-
tation capacity of bone marrow–derived immature DCs to
generate peptide/MHC class II complexes from proteins
expressed in recombinant 
 
E. coli
 
 (23). The peptide/MHC
II complexes were probed with the exquisitely sensitive
lacZ-inducible CD4 T cells to identify the bacteria express-
ing the recombinant antigen. We used this method to
identify the elusive autosomal CD4 T cell–stimulating 
 
H
 
loci. We report that the polymorphic 
 
H46
 
 locus first dis-
covered more than a decade ago (24), encodes the IL-4–
induced 
 
IL4i1
 
 gene that is located on chromosome 7. Fur-
thermore, we have defined the antigenic peptide within
the 
 
IL4i1
 
 gene presented by the A
 
b
 
 MHC class II to CD4
T cells, the antigenic relationship between the donor and
host strains as well as the antigen processing pathways used
by the APCs.
 
Materials and Methods
 
Mice, Cells, and Peptides.
 
Inbred mice were obtained from
The Jackson Laboratory or bred within the OLAC facility at UC
Berkeley. All procedures were performed in compliance with the
institutional ACUC guidelines. Procedures for immunization,
generation and maintenance of T cell lines and 
 
 
 
-galactosidase
(lacZ)-inducible T cell hybrids have been described (24, 25).
Briefly, the H46
 
a
 
-specific CD4 T cell line, 2PB-TH3 was gener-
ated by immunizing the congenic B10.129-
 
H46
 
b
 
H47
 
b
 
 (21M)
with C57BL/10J (
 
H46
 
a
 
H47
 
a
 
) splenocytes and was provided by
Dr. Derry Roopenian (The Jackson Laboratory, Bar Harbor,
ME). The T cells were used to generate the lacZ-inducible CD4
T cell hybrid TH3Z by fusing them with the lacZ-inducible fu-
sion partner, BWZ.36 (25).
Bone marrow cells obtained from the thigh bone of C57BL/6J
(B6) or 129 P3/J (129/J mice) were cultured with RPMI 1640
supplemented with 5% fetal bovine serum (Hyclone), 10 ng/ml
GM-CSF (Biosource International), 2 mM glutamine, 50 
 
 
 
M
2-mercaptoethanol, 200 U/ml penicillin, 200 
 
 
 
g/ml streptomy-
cin, and 20 
 
 
 
g/ml gentamicin. After 5 d the characteristic imma-
ture DCs in the CD11c
 
 
 
, CD86
 
 
 
, and A
 
b
 
 
 
 low cultures were
greater than 65% by FACS
 
®
 
 analysis and are referred to as bone
marrow–derived immature DCs (BMDCs) and used as APCs.
Peritoneal macrophages were elicited by an intraperitoneal injec-
tion of aged thioglycolate (Difco). The mice were killed 4 d later,
the macrophages harvested by peritoneal lavage with PBS, plated
out in dishes in complete RPMI medium, and allowed to adhere
at 37
 
 
 
C. After 2 h the nonadherent cells were washed away and
the remaining cells were cultured overnight in complete RPMI
medium supplemented with 100 U/ml IFN-
 
 
 
 (Genzyme). B
cells were obtained from the spleen and purified by MACS
 
®
 
 sys-
tem (Auburn, CA) with CD45R/B220-FITC conjugated mAb
(BD Biosciences). Purified B cells were cultured with 1 
 
 
 
g/ml
IL-4 (Biosource International) for 6 h. The peptides with the se-
quences shown in Fig. 5 and Fig. 6 were synthesized, purified by
HPLC, and confirmed by mass spectrometry.
 
T Cell Activation Assays.
 
LacZ-inducible T cell hybrids were
cocultured overnight with APCs from mice, or cells that had in-
gested transformed bacteria, were transfected with cDNAs, or
pulsed with exogenous peptides. In some experiments the APCs
were preincubated with anti-H2-D
 
b
 
 (B22.249) or anti-I-A
 
b
 
 (M5/
114.5.2) mAb for 1 h at 4
 
 
 
C before coculture with T cells. TheT
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results shown are the lacZ activity measured as the absorbance at
595 nm (with 635 nm as the reference wavelength) of the chro-
mogenic product released after cleavage of the substrate chlo-
rophenol red 
 
 
 
-pyrranoside (25).
 
cDNA Library and Recombinant Constructs.
 
PolyA
 
 
 
 mRNA
from day 5 BMDCs was used for the construction of the cDNA
library using the cDNA synthesis kit from Invitrogen. The
cDNA fragments were inserted unidirectionally into the pLEX
prokaryotic expression between the EcoRI/NotI sites and used
to transform GI724 competent bacteria to yield 
 
 
 
10
 
7
 
 cfu with an
average insert size of 0.5–3 kbp. The 5
 
 
 
 forward and 3
 
 
 
 reverse
PCR primers for the DNA constructs used here are shown be-
low. All primers included EcoRI and XbaI restriction sites except
those used for amplification of IL4i1 gene which contained
EcoRI and NotI sites to allow cloning into appropriate expres-
sion vectors (Table I).
First strand cDNA from polyA
 
 
 
 mRNA from day 5 BMDC
from B6, 129/J, or 21M mice was used to obtain the full-length
 
IL4i1
 
 homologues. PCR was performed using the high fidelity
Pfu Turbo polymerase system (Stratagene). The PCR products
were purified by agarose gel, sequenced directly with gene-spe-
cific primers, and subcloned into pLEX, pcDNA3, or the MSCV
IRES GFP retroviral vector which includes the IRES-green fluo-
rescent protein (GFP) to allow detection of transduced cells. The
point mutants 
 
H46
 
a
 
 P8L and A22M were prepared using the
Stratagene QuickChange Site-Directed Mutagenesis Kit.
 
Expression Cloning.
 
Bacterial transformants were grown and
induced to express the cDNA encoded proteins according to in-
structions (PL Expression System; Invitrogen). Briefly, 2 
 
 
 
 10
 
4
 
transformants were plated out on drug selection agar plates and
incubated overnight at 30
 
 
 
C. The colonies were harvested and
resuspended in the culture medium. The transformant density
was determined by OD
 
600
 
 (OD 1.0 
 
  
 
2 
 
 
 
 10
 
9
 
 cells/ml) and the
bacteria were plated out in 96-well round bottomed plates at 10–
20 cfu/well in 100 
 
 
 
l medium. After 24–36 h at 30
 
 
 
C when the
cultures had reached a 0.5 OD
 
600
 
, 5 
 
 
 
l of each well was replica
plated into a separate 96-well plate containing 100 
 
 
 
l medium/
well and cultured for 1–2 h at 30
 
 
 
C to attain log growth. Induc-
tion medium containing 10 
 
 
 
g/ml L-tryptophan was then added
and the incubation continued for 3 h at 37
 
 
 
C. The number of
transformants was again estimated by OD
 
600
 
 and bacteria were
transferred to 96-well plate to obtain a final concentration of 5 
 
 
 
10
 
6 
 
cfu/well and were used as the antigen source. The BMDCs
from 129/J mice were resuspended in RPMI medium without
fetal bovine serum and antibiotics and 10
 
5
 
 cells/well were incu-
bated with the induced bacteria for 1 h at 37
 
 
 
C to allow phagocy-
tosis. These plates were centrifuged for 2 min at 1,500 rpm, the
supernatant was removed, and 10
 
5
 
 TH3Z hybridoma cells in me-
dium containing 100 
 
 
 
g/ml gentamicin (to eliminate residual
bacteria) were added to each well. T cell activation was measured
as their lacZ response described above.
 
A
 
b
 
 Competitive Peptide Binding Assay.
 
The ability of peptide
analogs to bind A
 
b
 
 was determined by incubating A
 
b
 
-L cell trans-
fectants with 10 
 
 
 
M E
 
 
 
56–73 peptide (ASFEAQGALANIA-
VDKA) together with varying concentrations of the indicated
competitor peptides. After overnight incubation, the cells were
stained with Yae mAb specific for the E
 
 
 
/A
 
b
 
 complex and PE-
conjugated goat anti–mouse Ig and analyzed by flow cytometry.
The mean fluorescence intensity values were used to calculate the
percent inhibition. Both the E
 
 
 
 peptide and the Yae mAb super-
natant were gifts of A. Rudensky (University of Washington).
 
Transfections and Retroviral Transduction.
 
Simian COS7 (COS)
cells were electroporated in 270 mM sucrose, 7 mM sodium
phosphate at pH 7.4, and 1 mM MgCl
 
2
 
 with either full-length
IL4i1 genes from the B6, 129/J or the 224–26 fragment sub-
cloned in the pcDNA3 vector using the BTX800 electroporator.
The electrode had a 1.9-mm gap-prong and was set to deliver 5
99 ms pulses at 700 V. 2 d later the cells were titrated and cocul-
tured with the TH3Z T cells. Antigen-expressing retrovirus su-
pernatants were prepared using 293T as packaging cells. The cells
were transiently transfected with B6 or 129/J derived full-length
 
IL4i1
 
 gene in the MIG vector together with pGP-KV plasmid
encoded Moloney murine leukemia virus structural genes, 
 
gag-pol
 
(26), and VSV-G plasmids (27) by Superfect transfection as de-
scribed (QIAGEN). After 24 h the supernatants were filtered
through a 0.45 
 
  
 
filter and 4 
 
 
 
g/ml polybrene was added before
infection. Bone marrow cultures of 129/J mice plated out in a
24-well plate at 10
 
6
 
 cells/well were infected with the retroviral
supernatants after 2 d. The plate was centrifuged at 2,500 rpm for
2 h and the medium was replaced (28). After 2 d in culture 
 
 
 
8–
10% CD11c
 
 
 
 cells were found to express the vector encoded
GFP marker and used as APCs.
 
Table I.
 
Oligonucleotide Primers
 
Construct Forward (5
 
 
 
–3
 
 
 
) Reverse (5
 
 
 
–3
 
 
 
) Figure
 
 
 
N1
 
CCGGAATTCCATCACGTGTTCGTGGAGACT TGTAAAACGACGGCCAGTGC 5, A and B
 N2 CCGGAATTCCATGAGTGGCATGGTCATGGG TGTAAAACGACGGCCAGTGC 5, A and B
 N3 CCGGAATTCCATTCGCAAAGAGGAAGTGAG TGTAAAACGACGGCCAGTGC 5, A and B
 C1 GGTGACGCTCTTAAAAATTAAGCC GACTCTAGACGTTTCCACCAACAAGTG 5, A and B
 C2 GGTGACGCTCTTAAAAATTAAGCC GACTCTAGAATATATATTCTGGTGGGC 5, A and B
 C3 GGTGACGCTCTTAAAAATTAAGCC GACTCTAGATTGCGATTAGGAGTGGTC 5, A and B
H46b CCGGAATTCCATGTCAGCCCAGATGAACAG GACTCTAGATTGCGATTAGGAGTGGTC 6, A–C
H46b
P L
CAGATGAACAGGAGCTCTCTCACAAACAC GTGTTTGTGAGAGAGCTCCTGTTCATCTG 6, B and C
H46b
A M
GAGGGGCAGCAACACATGTTTGTGGAGGCCA TGGCCTCCACAAACATGTGTTGCTGCCCCTC 6, B and C
IL4i1 CCGGAATTCATGGCTGGGCTGGCCCTG ATAGTTTAGCGGCCGCTTGCGATTAGGAGTGGT 7, B, C, and DT
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Results and Discussion
CD4  TH3Z Recognize a Polymorphic Antigen Presented by
the Ab MHC II Molecule. As the first step toward the iden-
tification of CD4 T cell antigens, we generated a lacZ in-
ducible CD4  T cell hybridoma TH3Z (25). We used the
CD4 T cell clone 2PB-TH3 that was specific for the
mouse H46 antigen based upon its reactivity to a panel of
congenic recombinant mice (24). This genetic analysis of
the H46 locus had indicated that it was located within or
was regulated by a gene within the H4 complex on chro-
mosome 7 of C57BL/6 (B6) mice. In contrast to the H47
locus, located in the same H4 complex that elicited a CD8
T cell response, the closely linked H46 locus elicited
a CD4 T cell response when 129/J-derived congenic
B10.129/J-H46b,H47b (21M) mice were immunized with
B10 or B6 spleen cells (6, 24). Accordingly, the lacZ activ-
ity was stimulated only when the TH3Z T cell hybridoma
was cultured with donor B6-derived splenocytes, macro-
phages, or bone marrow cultures enriched for dendritic
cells (BMDCs), but not with the same cell types from the
MHC-matched 129/J strain (Fig. 1 A). Furthermore, the
TH3Z response required expression of the Ab MHC II
molecule because mAb specific for Ab, but not Db MHC
class I molecules inhibited its response to the APC (Fig. 1
B). The TH3Z hybridoma was therefore specific for a
polymorphic antigen that was presented by the Ab MHC II
molecule in the B6 background.
Interestingly, BMDCs derived from B6 mice were by far
the most potent APCs in comparison to splenocytes or
peritoneal macrophages. To identify the optimal source of
the antigen we tested the APC function of B6 bone mar-
row cultures after different days in culture. On a per cell
basis the TH3Z stimulating activity in bone marrow cells
was low on day 0, but increased dramatically during the
next 2 d, reached its peak on day 3, and remained at this
level for up to 6 d of culture (Fig. 1 C). The expression of
the TH3Z stimulating activity correlated well with a con-
comitant increase in the CD11c  cells in the bone marrow
cultures strongly suggesting that the antigen gene was ex-
pressed in immature DCs (unpublished data). We therefore
chose day 5 BMDCs as the optimal source of mRNA to
screen for the TH3Z stimulating antigen gene.
Generation of CD4 T Cell–stimulating Peptide/MHC Class
II Ligands from Precursors Expressed in Recombinant Bacteria.
We had previously shown that recombinant E. coli express-
ing heterologous proteins can serve as an antigen source for
generating peptide/MHC class II complexes in activated
macrophages (29, 30). The observed efficiency was ade-
quate for screening small prokaryotic genomes such as that
of Listeria monocytogenes for antigens recognized by lacZ in-
ducible CD4 T cells. To determine if the efficiency of in-
troducing exogenous proteins into the MHC class II path-
way could be further improved we compared peritoneal
macrophages and BMDCs as APCs for processing exoge-
nous ovalbumin to OTIIZ T cells. Both macrophages and
immature BMDCs generated the OVA peptide/Ab com-
plex from recombinant E. coli expressing OVA (Fig. 2 A).
The BMDCs were, however, consistently superior APCs
in their requirement for lower number of E. coli to obtain a
detectable T cell response as well as in stimulating a higher
magnitude of the OTIIZ response. Similar results were also
observed with the OVA/Ak and HEL/Ak-specific T cell
hybridomas (unpublished data). The approximately three-
fold increase in efficiency encouraged us to undertake the
task of screening cDNA libraries from mammalian cells that
contain tens of thousands of different proteins as potential
precursors for the antigenic peptide.
Based upon these results we devised a strategy schemati-
cally outlined in Fig. 2 B to search for CD4 T cell stimu-
lating antigens using recombinant E. coli as the antigen
source and BMDCs as recipient APCs. We planned first to
construct a cDNA library in a prokaryotic expression vec-
tor which would allow expression of the antigenic precur-
sor proteins in transformed bacteria. We chose to use the
commercially available pLEX vector because it allows reg-
ulated transcriptional control in the presence of tryptophan
(Trp) thereby reducing the chance that potentially toxic
proteins would be excluded from the bacterial pools. Sec-
ond, we planned to screen the potential precursor pools by
feeding the bacteria to BMDCs and to probe them with
Figure 1. TH3Z hybridoma recognizes a polymorphic H antigen
which is highly expressed in BMDCs and is presented by the Ab MHC II
molecule. (A) The indicated number of cells derived from C57BL/6 (B6)
or MHC-matched 129/J mice were cocultured with the lacZ-inducible
TH3Z hybridoma. (B) 105/well B6 spleen cells were cultured with
TH3Z T cells in the presence of the indicated mAb or medium alone. (C)
Bone marrow cells were cultured for the indicated days and varying num-
ber of cells were used as APCs for stimulating TH3Z T cells. The lacZ re-
sponse of the TH3Z hybridoma after an overnight incubation was deter-
mined after lysis of the cultures and addition of the lacZ substrate CPRG.
The absorbance of the cleaved chlorophenol red product at 595 nm is
shown for each culture.T
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the TH3Z cells for the presence of their cognate pep-
tide/Ab ligand. If precursor pools were detected individual
bacteria harboring the antigenic cDNA could be identified
by cloning and rescreening those in the original well of the
master plate.
Isolation of the TH3Z-stimulating Antigen Gene. A cDNA
library was prepared from polyA  mRNA isolated from day
5 B6 BMDCs because they were by far the most potent
stimulators of TH3Z T cell response (Fig. 1, A and C). The
cDNA library was screened in pools of  10 cfu/well using
immature BMDCs from the host 129/J strain as APCs be-
cause they did not express the cognate antigen (Fig. 1 A).
The TH3Z response to pool #224, one of the approxi-
mately 1,000 different pools screened, showed a response
that was above that of the other pools (Fig. 3 A). Pool 224
was fractionated into individual colonies several of which
strongly stimulated the TH3Z response in the rescreen (Fig.
3 B). One of these bacterial colonies was designated 224–26
and selected for further analysis. A second clone 296–76 was
also identified in the screen which after sequence analysis
was found to be identical to clone 224–26.
The TH3Z response to 224–26 was antigen-specific
and restricted by the Ab MHC II molecule. The 224–26
bacteria failed to stimulate the OVA/Ab-specific OTIIZ T
cells (Fig. 3 C). The TH3Z response to 224–26 bacteria
was enhanced over 100-fold when the bacteria were cul-
tured with tryptophan that activated expression of the in-
sert in the pLEX vector. Furthermore, TH3Z response to
224–26 bacteria was completely inhibited in the presence
of anti-Ab MHC II mAb while anti-Db MHC I specific
mAb had no effect (Fig. 3 D). We conclude that clone
224–26 allowed the expression of the peptide/Ab complex
in the recipient 129/J APC that was recognized by the
TH3Z T cells most likely because clone 224–26 encoded
the antigenic peptide.
The Murine H46a Locus Encodes the IL4i1 Gene on Chro-
mosome 7. The nucleotide sequence of 224–26 cDNA was
determined (Fig. 4 A). A search of the sequence databases at
the National Center for Biotechnology Information showed
that this sequence was identical to nucleotides 1,680–2,059
encoding the 87 COOH-terminal amino acids of the IL-4–
induced IL4i1 gene (accession no. NM_010215). The IL4i1
gene was originally identified as an IL-4–induced transcript
in B cells from BALB/c strain (31). In agreement with the
identity of the IL4i1 gene in the B6 background analyzed
here the Ab expressing BALB.B spleen cells were also capa-
ble of stimulating the TH3Z response (unpublished data).
Furthermore, the TH3Z response to purified B cells was
observed only after the B cells had been cultured in IL-4
(Fig. 4 B). This result was consistent with the notion that
the IL-4–stimulated transcription of the IL4i1 in B cells led
to the generation of the peptide/Ab complex.
An analysis of the predicted 630 amino acid protein se-
quence of the full-length IL4i1 gene revealed a number of
potential N-linked glycosylation sites, tyrosine phosphory-
lation sites as well as a flavin cofactor binding domain, sug-
gesting that it is a member of the flavin monoamine oxidase
family of enzymes (http://www.ebi.ac.uk/interpro/). The
analysis also showed that it contains a hydrophobic ER
translocation signal sequence at its NH2 terminus and is
therefore predicted to be translocated into the ER. It has
been suggested that the IL4i1 gene may be involved in sys-
temic lupus erythematosus because of its genomic location
(31, 32). However, the normal function of this protein and
its intracellular location have not been experimentally es-
tablished. In addition, the impact of the natural polymor-
phisms (see below) in the IL4i1 gene on its function re-
mains to be determined.
The H46 locus had previously been genetically mapped
to the H4 complex on chromosome 7 (24). To determine
Figure 2.  BMDCs are superior to
peritoneal macrophages in the pre-
sentation of antigen expressed in E.
coli. (A) Varying numbers of E. coli
expressing OVA or vector alone
were fed to 105 peritoneal macro-
phages (M ) or BMDCs. After a brief
incubation, OVA/Ab-specific OTIIZ
T cells were added and their lacZ re-
sponse measured after an overnight
incubation. (B) A schematic repre-
sentation of the strategy for ex-
pression cloning CD4 T cell–stimu-
lating antigens. A cDNA library
from appropriate donor tissue is pre-
pared in a prokaryotic, tryptophan
inducible, expression vector. The
transformed E. coli are plated in small
pools in a 96-well plate. Expression
of the cDNA encoded proteins is
obtained in a replica plate of the
bacterial cultures by inducing with
tryptophan (Trp). The bacterial pools containing the putative antigen are fed to host day 5 BMDCs which phagocytose the bacteria, process and present
the antigen/MHC II complexes. The presence of these CD4 T cell ligands is detected by the lacZ response of the CD4 T cell hybrid. The individual
bacterial clone is then identified by subcloning the bacteria in the replicate well from the “Master” plate and repeating the screen. See Materials and
Methods for details.T
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whether the 224–26 cDNA encoding the antigenic pre-
cursor mapped to the same chromosomal location or was
regulated by another gene located on chromosome 7, we
searched the mouse genome database (http://www.
informatics.jax.org/). Most significantly, the IL4i1 gene was
located on chromosome 7 within 3 centi-morgan (cM) of
the previously suggested location of the H46 locus. Based
upon the current map of chromosome 7 both CD4 and
CD8 T cell defined H46 and H47 polymorphic loci are lo-
cated within 5.4 cM and close to the pink-eyed dilute lo-
cus p (Fig. 4 C). These data are in complete agreement
with the previous genetic analysis and confirm that the
H46 locus is physically located on chromosome 7. Note
that the close linkage seen here between the CD8 (H47)
and CD4 (H46) T cell defined autosomal loci was also seen
earlier for the Y-chromosome encoded CD8 (Smcy, Uty)
and CD4 (Dby) T cell defined loci (5). Thus, the discovery
of the tight linkage between CD4 and CD8 T cell defined
loci on the sex as well as autosomal chromosomes is in
complete agreement with the original Roopenian hypoth-
esis that the CD8 and CD4 T cell–stimulating H loci must
cosegregate (33).
Identification of the Antigenic Peptide Encoded by 224–26
cDNA. To understand the molecular basis for the antige-
nicity of the H46 locus we defined the putative antigenic
peptide within the 224–26 encoded polypeptide. We gener-
ated a series of deletions at the 5  and 3  ends of the 224–26
cDNA (Fig. 5 A). The deleted fragments were recloned in
the original pLEX vector and recombinant E. coli expressing
the truncated polypeptides were tested for antigenic activity
after feeding BMDC from 129/J mice (Fig. 5 B). All dele-
tions of 106 or more nucleotides from the 5  end ( N1) or
309 nucleotides from the 3  end ( C1) caused complete loss
of antigenic activity. Based upon the full antigenic activity
of the  C2 and the loss of antigenic activity of  N1 and
 C1 constructs we inferred that the antigenic activity
within the 224–26 cDNA was dependent upon the presence
of nucleotides 52–106 encoding aa18–36 (Fig. 4 A).
To directly establish the validity of this assignment as well
as to determine whether the antigenic activity was con-
tained within the peptide itself or was somehow induced in
the recipient APC by the 224–26 polypeptide we tested a
panel of overlapping synthetic peptides using 129/J BMDC
as APC (Fig. 5, C and D). Peptide 24–37, but not peptides
Figure 3. Identification of the TH3Z cognate antigen by
expression cloning. (A) A prokaryotic cDNA expression li-
brary from day 5 BMDCs derived from B6 mice was
screened in 129/J-derived BMDCs using the lacZ-induc-
ible TH3Z T cells as described in Fig. 2 B. The lacZ re-
sponse of TH3Z hybridoma to the bacterial pools in one of
the 96-well plates screened is shown indicating the higher
than background response to pool 224. (B) TH3Z response
to individual bacterial colonies isolated from pool 224.
Clone 224–26 was selected for further analysis. (C and D)
The TH3Z response to clone 224–26 is antigen-specific
and Ab MHC class II restricted. Clone 224–26 bacteria
were cultured in medium alone ( Trp) or in medium
containing the transcriptional inducer tryptophan ( Trp).
Varying number of bacteria were fed to 105 129/J BMDCs/
well. 105 TH3Z or the OVA/Ab-specific OTIIZ T cells
were added and their lacZ response was assayed after over-
night culture. (D) The right panel shows the TH3Z re-
sponse to 129/J BMDC that were fed 106 clone 224–26
bacteria/well in medium alone or in the presence of mAb
specific for the Ab MHC II or the Db MHC I molecules.T
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18–32 or 28–42 stimulated a strong TH3Z response at sub-
micromolar concentrations. The antigenic activity was
therefore contained within the 14 amino acids of peptide
24–37. Additional analogs of peptide 24–37 were prepared
to define the N- and COOH-terminal boundaries of the
antigenic epitope. The antigenic activity of all the analogs
with up to three additional amino acids at the NH2 termi-
nus and three fewer amino acids at the COOH terminus
(p21–34) was comparable to that of p24–37. From these
data we infer that the 11-mer sequence HAFVEAIPELQ
(aa 24–34) within the 224–26 cDNA defines the core anti-
genic epitope that is presented by the Ab MHC II molecule.
Consensus sequence motifs for peptides presented by
MHC II have been difficult to define. Nevertheless system-
atic mutagenesis of single amino acids has suggested that
the Ab bound peptides share an aromatic tyrosine or phe-
nylalanine residue at the i anchor position, an uncharged
amino acid at the i 5 position, with no positively charged
residues at the i 8 position (34). The H46a peptide defined
by the sequence HAFVEAIPELQ shares each of these fea-
tures as well. Assuming that the phenylaline (F) occupies
the i position, the i 5 and i 8 residues are uncharged pro-
line (P) and a nonpositively charged glutamine (Q) resi-
dues. However, systematic amino acid substitutions are re-
Figure 4. TH3Z T cell stimulating H46 lo-
cus encodes the IL-4–induced IL4i1 gene lo-
cated on chromosome 7. (A) Nucleotide se-
quence and the predicted translation of the
insert in plasmid DNA of bacterial clone 224–
26. The antigenic peptide experimentally iden-
tified below is boxed. (B) IL-4–stimulated B
cells derived from B6 mice stimulate TH3Z T
cells. Purified B cells from donor B6 or 129/J
strains were cultured in medium alone or with
IL-4 for 6 h. Varying number of these cells
were used as APC for TH3Z T cells. Data show
the lacZ response of TH3Z cells after overnight
culture. (C) The H46 locus is defined by the
IL4i1 gene that is presented as a peptide/Ab
MHC II complex. The H46 locus is closely
linked to the H47 locus that encodes a peptide
presented by the Db MHC I molecule and the
pink-eyed dilution locus p on murine chromo-
some 7. The map positions indicated in centi-
morgan (cM) are based upon the mouse ge-
nome database (http://www.informatics.jax.
org/) and exclude other genes located in this
region.
Figure 5. Identification of t he
TH3Z-stimulating  H46a antigenic
epitope within clone 224–26. (A)
Schematic representation of the de-
letion constructs used to identify the
antigenic activity encoded within
clone 224–26.  N1 3 represent
deletions that truncate the NH2 ter-
minus of the potential polypeptide
while  C1 3 cause COOH-termi-
nal deletions. The specific nucle-
otides included in the constructs are
shown in parentheses and the region
with antigenic activity is indicated
by a shaded oval. (B) The TH3Z T
cell lacZ response to the N- and
COOH-terminal deletion constructs
expressed in E. coli that were fed to
129/J BMDC. (C) Overlapping syn-
thetic peptides used for fine mapping
the TH3Z T cell epitope. The num-
bering refers to the predicted protein
sequence of clone 224–26 shown in
Fig. 4 A. The core sequence re-
quired for antigenic activity is boxed. (D) 129/J BMDCs were incubated for 60 min with the indicated concentration of the synthetic peptides shown in
C. The TH3Z T cells were added and their lacZ response measured after an overnight culture.T
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quired to confirm the importance of these positions to the
Ab binding characteristics of the H46a peptide.
A Single Amino Acid Polymorphism Defines the Antigenicity
of H46 Alleles. To determine the relationship between
the donor and host strains that define the polymorphism at
the H46 locus we first analyzed BMDC mRNA in the
B6, the congenic B10.129/J-H46b-H47b (21M) and the
parental 129/J strains by Northern blot. Transcripts hybrid-
izing with the 224–26 probe were expressed in each strain
(unpublished data). To determine if there were any se-
quence polymorphisms we generated by RT-PCR the
21M and 129/J-derived fragments corresponding to the
224–26 cDNA from B6 mice (Fig. 6 A). The nucleotide
sequences of these fragments were identical to that ex-
pressed in the B6 strain except for three nucleotide substi-
tutions C23 T, G73 A, and C74 T. These changes
caused the Pro8 Leu and Ala25 Met substitutions in the
predicted amino acid sequence of the H46b allele in the pa-
rental 129/J as well as its congenic derivative 21M strains.
Both amino acid substitutions were located in the prox-
imity of the H46a antigenic peptide. The P8 L substitu-
tion was located 18 residues upstream while the A25 M
substitution was contained within the antigenic peptide. To
determine which one or both of these substitutions affected
the antigenicity of the H46a (P-A) versus the H46b allele
(L-M), we prepared mutant constructs in the pLEX bacte-
rial expression vector that would yield precursors with only
a single (P L or A M) substitution (Fig. 6 B). Recombi-
nant E. coli expressing the H46a, H46b as well as the mutant
constructs were fed to 129/J BMDCs and tested for their
ability to stimulate the TH3Z T cells (Fig. 6 C). Clearly the
B6-derived  H46a and the mutant H46a P  L precursors
were active in stimulating the TH3Z response while the al-
lelic 129/J-derived H46b and the H46a A M precursors
were completely inactive at all concentrations tested. Thus,
the antigenicity of the H46a allele was dependent upon the
single A M substitution within the antigenic peptide and
was not affected by the upstream P L substitution.
To directly establish that the difference in antigenicity
was due to the A M substitution we also synthesized the
14 amino acid H46b (residues 24–37) homologue of the
H46a antigenic peptide (Fig. 6 D). In an exogenous pre-
Figure 6. Non-self at the H46 locus is defined by a sin-
gle amino acid polymorphism. (A) The deduced amino
acid sequences of H46 cDNA from the B6 (H46a), the
congenic 21M (H46b), and the parental 129/J (H46b)
mouse strains. The cDNA fragments corresponding to the
B6-derived clone 224–26 were obtained by RT-PCR.
The H46a antigenic peptide is boxed. (B) Constructs con-
taining the H46a and H46b wild-type as well as single point
mutations of each of the two polymorphic residues H46a
P L and H46a A M subcloned into the bacterial expres-
sion vector pLEX. (C) TH3Z lacZ response to 129/J
BMDCs fed with bacteria expressing the constructs shown
in B. (D) Amino acid sequences of the synthetic peptide
representing the H46a and H46b homologues. Bold letters
indicate the single amino acid polymorphism between the
B6 and 129 strains. (E) TH3Z lacZ response to the H46a
and H46b peptides presented by 129/J-derived BMDCs.
(F) The relative Ab MHC II binding property of H46a and
H46b peptides compared with the Ak MHC II binding
peptides HEL34–45 and OVA247–265. The data show the
varying concentrations of indicated peptides cause compet-
itive inhibition of the binding of the E  peptide to the Ab
MHC II on Ab-L cells. The E /Ab complex was detected
with the Yae mAb by flow cytometry as described in Ma-
terials and Methods.T
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sentation assay only the H46a peptide was active, and the
H46b peptide with a single A M substitution was com-
pletely inactive even at 100-fold higher concentration
(Fig. 6 E). Thus, the difference in antigenicity of the two
H46 alleles could be directly attributed to the single ala-
nine to methionine amino acid substitution within the
core antigenic sequence.
The lack of TH3Z response to the H46b peptide could
have been due to inability of this peptide to bind the Ab
MHC II molecule. We compared the two H46 analogs for
their ability to compete with the E  peptide for binding to
Ab MHC on the surface of Ab expressing L cells. Differ-
ences in the level of the E /Ab complex were monitored
by flow cytometry using the Yae mAb (35). In contrast to
Ak binding HEL34–45 and OVA247–265 peptides which
competed poorly, both H46a and H46b peptides were
comparable in their ability to compete with the E  peptide
for binding Ab (Fig. 6 F). Thus, the failure of TH3Z T cells
to recognize the H46b peptide is likely due to changes in
the conformation of the peptide and/or the Ab surface
caused by the single Ala Met substitution which may in-
terfere with TCR recognition, rather than a simple failure
to bind Ab MHC. It would be interesting to determine
whether the H46b peptide, which is predicted to be pre-
sented by DCs in the 129/J strain, is immunogenic in the
H46a B6 strain.
The H46a Peptide/Ab Complex Is Generated via an Endoge-
nous Processing Pathway. MHC II molecules acquire their
peptides primarily from exogenous sources but can also
present some endogenously synthesized proteins (11). The
IL4i1 gene was originally identified as a transcript induced
in IL-4–treated B cells, but is now recognized to be consti-
tutively expressed in many tissues (reference 32; and http://
www.ncbi.nlm.nih.gov/UniGene/). The intracellular loca-
tion of the IL4i1 protein is not known, and the presence of
an ER translocation signal raised the possibility that IL4i1
precursor may be secreted by other cells and acquired by
professional APC as an exogenous antigen. Alternatively,
because DCs appear to constitutively express the IL4i1 gene
as judged by Northern blots and direct APC function (Fig.
1, A and C), it is possible that the H46/Ab epitope is gener-
ated via an endogenous processing pathway.
To distinguish between these two possibilities, we first
isolated the full-length cDNAs for the IL4i1 gene from the
B6 (H46a) and 129/J (H46b) strains. Similar to the COOH-
terminal fragments represented by the 224–26 cDNA the
full-length cDNA could also serve as antigenic precursors
for the TH3Z epitope whether they were first expressed in
E. coli and fed to 129/J BMDC (unpublished data) or ex-
pressed directly in the 129/J DCs via retroviral transduc-
tion (Fig. 7 A). Likewise transient transfection of the B6
but not 129/J-derived full-length IL4i1 cDNA together
Figure 7. The H46a/Ab complex is
generated from the full-length IL4i1
gene via an endogenous presentation
pathway. (A) 129/J BMDCs were
transduced with retroviruses express-
ing either vector alone or the B6 or
129/J-derived full-length IL4i1
cDNAs as described in Materials and
Methods. 2 d later the transduced
cells were titrated and used as APC
for TH3Z T cells. About 8–10% cells
expressed the retrovirus as indicated
by the presence of CD11c GFP 
cells. (B) COS cells were transiently
transfected with the indicated cDNA
constructs representing the Ab MHC
II subunits Ab
  and Ab
  together with
the B6 or 129/J derived full-length
IL4i1 genes or the 224–26 fragment.
After 48 h, indicated number of
transfected cells were cocultured with
TH3Z T cells and their lacZ response
was measured after overnight incuba-
tion. (C and D) The H46a/Ab
epitope is not acquired by BMDC
from other cells expressing the pre-
cursor gene. COS cells were trans-
fected with the B6-derived full-
length IL4i1 cDNA with or without
the Ab subunits. 2 d later indicated
numbers of transfected COS cells (C)
or BMDCs from B6 (H46a , Ab ) or
B10.D2 (H46a , Ab-). (D) were
added to 129/J BMDC (H46b, Ab ).
The lacZ response of TH3Z T cells
was obtained only when the H46a
precursor and the Ab MHC II is ex-
pressed in the same cells.T
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with Ab  and Ab  cDNAs in COS cells resulted in the ex-
pression of the TH3Z stimulating epitope and was com-
pletely dependent upon the presence of the Ab MHC II
(Fig. 7 B). Interestingly, the cytoplasmic 224–26 fragment
was insufficient for generating the TH3Z epitope in COS
cells, suggesting that other features of the full-length pro-
tein are required for its entry into and/or processing within
the MHC II processing compartments. These features re-
main to be identified.
The processing of the full-length precursor occurred via
an endogenous processing pathway. A mixture of 129/J
BMDCs and COS cells transiently transfected only with
B6-derived  IL4i1 cDNA failed to generate the TH3Z
ligand while COS cells expressing both the IL4i1 precursor
and Ab stimulated TH3Z cells strongly (Fig. 7 D). Simi-
larly, mixture of BMDCs from the H46a expressing
B10.D2, that lack the restricting Ab MHC II and 129/J
(H46b, H2b) derived BMDCs also failed to generate the
TH3Z stimulating ligand (Fig. 7 E). In contrast, mixture of
H46a and Ab expressing BMDCs from B6 and 129/J mice
were strongly stimulatory. Thus, whether the IL4i1 precur-
sor was expressed in COS cells or BMDCs, it could not be
used as an exogenous source by host 129/J-derived profes-
sional APCs. We therefore conclude that the generation of
the H46a/Ab epitope occurred via an endogenous MHC
class II processing pathway within the APCs. How the
IL4i1 is targeted to the MHC II processing pathway re-
mains to be determined.
In conclusion, we have established a generally applicable
method for the identification of CD4 T cell stimulating an-
tigens. This method allowed us to screen large cDNA li-
braries from the target tissue in professional APCs that were
generated from the host strain. Note that the ability to use
professional APCs as recipients for the screen is a significant
advantage because it obviates the necessity of generating
designer recipient cell lines expressing the appropriate
MHC II molecule, invariant chain, and DM (21). In fact,
not only are the cDNAs of the appropriate MHC II sub-
units unnecessary even the knowledge of which particular
MHC II presents the antigenic peptide is not essential. This
could be very important in human applications where mul-
tiple heterodimers are formed between the MHC II   and
  subunits and it is often difficult to unambiguously iden-
tify the MHC II molecules involved. We envisage that this
method will now permit identification of CD4 T cell anti-
gens involved in autoimmunity as well as tumors.
The identification of the polymorphic H46 locus and its
antigenic peptide presented by the Ab MHC II molecule
shows that even a subtle, single amino acid difference be-
tween self and nonself can lead to potent CD4 T cell re-
sponses (24). The foreign H46a peptide differed only in a
single conserved methionine to alanine substitution in the
self H46b peptide. Single amino acid substitution have of-
ten been observed among CD8 T cell stimulating H pep-
tides and their self-homologues (2, 6, 36), but all the
known H epitopes recognized by CD4 T cells have gener-
ally differed in several amino acids from their self counter-
parts. For example, the Y-chromosome encoded Dby gene
yields different peptides presented by the Ab, Ek, and HLA-
DQ5 MHC II molecules (5, 37). Each of these peptides
differ in at least 3 amino acid residues from their counter-
parts in the X-chromosome encoded Dbx gene, and unlike
the H46a precursor, they can be presented by the DCs
when expressed in other cells. The distinction between the
presentation of H46a versus Dby peptides via endogenous
and exogenous processing pathways raises an interesting
and now testable hypothesis. Large differences between the
tolerated self and foreign nonself may not be required
when the processed peptides are generated endogenously
within the professional APCs: a distinct advantage of being
at the right place all the time.
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